Molecular histogenesis of posttransplantation lymphoproliferative disorders
- 31 July 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 102 (10) , 3775-3785
- https://doi.org/10.1182/blood-2003-05-1683
Abstract
Posttransplantation lymphoproliferative disorders (PTLDs) represent a serious complication of solid organ transplantation. This study assessed the molecular histogenesis of 52 B-cell monoclonal PTLDs, including 12 polymorphic PTLDs (P-PTLDs), 36 diffuse large B-cell lymphomas (DLBCLs), and 4 Burkitt/Burkitt-like lymphomas (BL/BLLs). Somatic hypermutation (SHM) of immunoglobulin variable (IgV) genes documented that most monoclonal B-cell PTLDs (75% P-PTLDs, 91.3% DLBCLs, 100% BL/BLLs) derive from germinal center (GC)-experienced B cells. B-cell lymphoma 6 (BCL6) mutations occurred in 25% P-PTLDs, 60.6% DLBCLs, and 75.0% BL/BLLs. A first histogenetic category of PTLDs (31.2% DLBCLs) express the BCL6+/multiple myeloma oncogene-1 protein (MUM1-/+)/CD138- profile and mimic B cells experiencing the GC reaction, as also suggested by ongoing SHM in a fraction of these cases. A second subset of PTLDs (66.7% P-PTLDs and 31.2% DLBCLs) display the BCL6-/MUM1+/CD138- phenotype and mimic B cells that have concluded the GC reaction. A third histogenetic category of PTLDs (25.0% P-PTLDs and 31.2% DLBCLs) shows the BCL6-/MUM1+/CD138+ profile, consistent with preterminally differentiated post-GC B cells. Crippling mutations of IgV heavy chain (IgVH) and/or IgV light chain (IgVL) genes, leading to sterile rearrangements and normally preventing cell survival, occur in 4 DLBCLs and 1 BL/BLL that may have been rescued from apoptosis through expression of Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1). Overall, the histogenetic diversity of monoclonal B-cell PTLDs may help define biologically homogeneous categories of the disease. (Blood. 2003;102: 3775-3785)Keywords
This publication has 28 references indexed in Scilit:
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic LeukemiaThe Journal of Experimental Medicine, 2001
- EPSTEIN-BARR VIRUS-NEGATIVE LYMPHOPROLIFERATIVE DISORDERS IN LONG-TERM SURVIVORS AFTER HEART, KIDNEY, AND LIVER TRANSPLANT1Transplantation, 2000
- Cellular Origin of Human B-Cell LymphomasNew England Journal of Medicine, 1999
- TrueLeukemia, 1999
- Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.Journal of Clinical Investigation, 1998
- Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells.Journal of Clinical Investigation, 1997
- A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1British Journal of Haematology, 1996
- The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacementImmunology Today, 1994
- Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell deathCell, 1991
- Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).Journal of Histochemistry & Cytochemistry, 1984